BR112022024988A2 - Compostos e métodos para tratamento de infecções fúngicas - Google Patents

Compostos e métodos para tratamento de infecções fúngicas

Info

Publication number
BR112022024988A2
BR112022024988A2 BR112022024988A BR112022024988A BR112022024988A2 BR 112022024988 A2 BR112022024988 A2 BR 112022024988A2 BR 112022024988 A BR112022024988 A BR 112022024988A BR 112022024988 A BR112022024988 A BR 112022024988A BR 112022024988 A2 BR112022024988 A2 BR 112022024988A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
compounds
fungal infections
fungal
Prior art date
Application number
BR112022024988A
Other languages
English (en)
Inventor
joy Shaw Karen
Schlamm Haran
R Hodges Michael
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of BR112022024988A2 publication Critical patent/BR112022024988A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMPOSTOS E MÉTODOS PARA TRATAMENTO DE INFECÇÕES FÚNGICAS. A presente invenção refere-se a composições e métodos de uso das mesmas para o tratamento de infecções e doenças fúngicas.
BR112022024988A 2020-06-17 2021-06-16 Compostos e métodos para tratamento de infecções fúngicas BR112022024988A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040450P 2020-06-17 2020-06-17
PCT/US2021/037578 WO2021257670A1 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Publications (1)

Publication Number Publication Date
BR112022024988A2 true BR112022024988A2 (pt) 2022-12-27

Family

ID=79268375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024988A BR112022024988A2 (pt) 2020-06-17 2021-06-16 Compostos e métodos para tratamento de infecções fúngicas

Country Status (12)

Country Link
US (1) US20230233586A1 (pt)
EP (1) EP4167998A1 (pt)
JP (1) JP2023530936A (pt)
KR (1) KR20230024375A (pt)
CN (1) CN115884775A (pt)
AU (1) AU2021293911A1 (pt)
BR (1) BR112022024988A2 (pt)
CA (1) CA3187268A1 (pt)
IL (1) IL299057A (pt)
MX (1) MX2022016179A (pt)
TW (1) TW202214258A (pt)
WO (1) WO2021257670A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515599A (zh) * 2020-03-04 2022-12-23 安普利克斯制药公司 化合物在真菌感染的治疗中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
US11819503B2 (en) * 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Also Published As

Publication number Publication date
TW202214258A (zh) 2022-04-16
CN115884775A (zh) 2023-03-31
KR20230024375A (ko) 2023-02-20
WO2021257670A1 (en) 2021-12-23
MX2022016179A (es) 2023-04-20
CA3187268A1 (en) 2021-12-23
IL299057A (en) 2023-02-01
EP4167998A1 (en) 2023-04-26
JP2023530936A (ja) 2023-07-20
AU2021293911A1 (en) 2023-01-19
US20230233586A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
UY37480A (es) Nuevos derivados de quinolina
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
BR112021024236A2 (pt) Proteínas multiespecíficas
BR112022008365A2 (pt) Inibidores de cd73
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
CO2020013876A2 (es) Nuevos derivados de quinolina
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2022000481A2 (es) Inhibidores de enzimas
CL2020001147A1 (es) Compuestos antibacterianos
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
BR112021011325A2 (pt) Derivados de rapamicina
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AMPLYX PHARMACEUTICALS, INC. (US)

B25A Requested transfer of rights approved

Owner name: BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH)